A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.

Although ‘lean type 2 diabetes’ is not uncommon, clinicians must first exclude other causes including autoimmune, monogenic, ...

In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, ...

Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...

ASX health stocks fall o.92% over past five days as US President Donald Trump renews threat to impose tariffs on pharmaceutical imports.

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Along with announcing a 50% tariff on copper imports, The POTUS threatened to levy tariffs as high as 200% on pharmaceutical ...